Navigation Links
Oral bisphosphonate did not improve prognosis for patients with breast cancer
Date:12/7/2011

SAN ANTONIO Results from a German study demonstrated no improvement in disease-free survival among patients with breast cancer who were treated with dose-dense chemotherapy and the bisphosphonate ibandronate.

Volker Mbus, Ph.D., head of the department of obstetrics and gynecology at Klinikum Frankfurt Hchst GmbH in Frankfurt, presented the results from the German Adjuvant Intergroup Node Positive (GAIN) Study, at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

Mbus and his colleagues randomly assigned 3,023 patients with breast cancer to two different chemotherapy regimens and then further assigned them to 50 milligrams of oral ibandronate or observation. After a median follow-up of 38.7 months, "we found no significant difference between groups in the primary endpoint" of disease-free survival, Mbus said.

He described these results as "disappointing" compared with other studies. In the Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer (AZURE) trial, for example, Mbus said that the subgroup of postmenopausal patients showed an improvement in recurrence-free and overall survival.

"So far, clinical trials of adjuvant bisphosphonates in early breast cancer have shown variable results, independent from their application (oral compared with intravenous)," Mbus said.

More recently, two trials the Austrian Breast & Colorectal Study Group (ABCSG-12) and the Zometa-Femara Adjuvant Synergy Trial (ZO-FAST) have shown significant benefit in patients with hormone receptor-positive breast cancer who were postmenopausal and received an endocrine treatment only.

Mbus said that in the AZURE trial, 95 percent of patients received chemotherapy and only postmenopausal patients showed an improvement in the zoledronic acid group. "In our [GAIN] trial, all patients received dose-dense chemotherapy, and unfortunately, we could not show a benefit in any subgroup," he said. "We speculate that the high efficacy of dose-dense chemotherapy erases the potential effect of bisphosphonates, which is shown in patients with endocrine treatment only."


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Some bisphosphonates users unfamiliar with drugs possible side effects on oral health
2. New task force report on bisphosphonate use and atypical femur fractures in osteoporosis patients
3. Immediate bisphosphonate use with endocrine therapy reduced recurrence and increased survival in postmenopausal early breast cancer
4. A New Website Series Improves Appearance and Health City by City
5. CustomerCentric Selling and Kadient Announce Joint Event in Boston to Launch Strategic Partnership for Sales Enablement and Improvement
6. Exercise Success for People Over 50: Reports of Improved Fitness, Circulation and Balance
7. NationalCreditReport.com Reminds Consumers of Ways to Improve Credit Report and Score in 2010
8. Medical Transcription Services and EHR Provider MxSecure Launches New Enhanced Website with Goal of Improved Physician Productivity
9. Retired Military Brass Support First Ladys Call to Reduce Child Obesity, Improve Nutrition
10. NACDD Receives Two-Year Grant From Merck & Co., Inc. to Improve Diabetes Education
11. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... ... ... Another ER facility operated by First Choice Emergency Room opened yesterday ... is open 24 hours daily. , First Choice Emergency Room hosted a ribbon cutting ... High School band entertained attendees and accepted First Choice Emergency Room’s donation on behalf ...
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can be time ... preset onto their media," said Christina Austin - CEO of Pixel Film Studios. ... and easily add stylish color grades to their footage. A LUT is a Lookup ...
(Date:5/27/2016)... ... May 27, 2016 , ... Southland Log Homes , designer and ... frame barn kits, which can be found on its website at SouthlandLogHomes.com. , The ... plans, and they highlight the craftsmanship of timber post and beam construction. The ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... This campaign ... a stroke, which we as a society can control and change. , As nearly ... nearly every 40 seconds within the United States. Plus, with an estimated 129,000 of ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, 2016 , ... ... bolstered by inspiring human interest stories, which come courtesy of leaders in the nursing ... within the industry, from leading advocates and associations—namely Abilene Christian University. , As ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... May 25, 2016 Digital Health Dialog, ... it by the US Patent and Trademark Office ... includes proprietary processes for electronic opt-­in and processing ... wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for individuals ...
(Date:5/24/2016)... Cirujanos holandeses han puesto en ... médicos a compartir sus mejores prácticas por el mundo ... médicos de Europa, África, Asia ... aplicación, que combina la transmisión en vivo con mensajería ... Educación   "Imagine un médico de Medicines ...
(Date:5/24/2016)... 24, 2016  NxStage Medical, Inc. (Nasdaq: ... advancing renal care, today announced that Jeffrey H. ... the following schedule of investor conferences. Where applicable, a ... http://ir.nxstage.com/ .   ... NY, NY           Friday, June 10, 2016 1:30 p.m. ...
Breaking Medicine Technology: